RecruitingPhase 2ACTRN12610000291088
effect of alpha lipoic acid on cardiac autonomic function and platelet reactivity in type I diabetes
In patients with type I diabetes is alpha lipoic acid better than placebo for improvement of cardiac autonomic function and reduction of platelet reactivity?
Sponsor
Catholic University
Enrollment
60 participants
Start Date
Dec 1, 2009
Study Type
Interventional
Conditions
Summary
The present randomized study will evaluate the effect of alpha lipoic acid compared to placebo on cardiac autonomic function and platelet reactivity in type I diabetic patients
Eligibility
Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss
Inclusion Criteria1
- type I diabetes
Exclusion Criteria3
- cardiac ischemia
- inflammatory diseases
- neoplastic and hematologic diseases
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
alpha lipoic acid
dose: 800 mg once per day
duration of administration: 4 weeks
mode of administration: oral capsules
alpha lipoic acid dose: 800 mg once per day duration of administration: 4 weeks mode of administration: oral capsules
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000291088